Clinical Trial Update: Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors [Phase 1]

View source ↗

Summary

The trial update notes the Phase I study of the BIBW 2992 (afatinib) and BIBF 1120 (nintedanib) combination in solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Gilotrif (Afatinib)
• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED